1-10 of 10
Guido Marcucci
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL

Available to Purchase
Ibrahim Aldoss, Samer K. Khaled, Xiuli Wang, Joycelynne Palmer, Yan Wang, Jamie R. Wagner, Mary C. Clark, Jennifer Simpson, Jinny Paul, Vibhuti Vyas, Sheng-Hsuan Chien, Anthony Stein, Vinod Pullarkat, Amandeep Salhotra, Monzr M. Al Malki, Ahmed Aribi, Karamjeet Sandhu, Sandra H. Thomas, Lihua E. Budde, Guido Marcucci, Christine E. Brown, Stephen J. Forman
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (4): 742–753.
https://doi.org/10.1158/1078-0432.CCR-22-2038
Published: 16 February 2023
View articletitled, Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL
Open the PDF for Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL in another window
Includes: Supplementary data
Journal Articles

Targeted Delivery of microRNA-29b by Transferrin-Conjugated Anionic Lipopolyplex Nanoparticles: A Novel Therapeutic Strategy in Acute Myeloid Leukemia

Free
Xiaomeng Huang, Sebastian Schwind, Bo Yu, Ramasamy Santhanam, Hongyan Wang, Pia Hoellerbauer, Alice Mims, Rebecca Klisovic, Alison R. Walker, Kenneth K. Chan, William Blum, Danilo Perrotti, John C. Byrd, Clara D. Bloomfield, Michael A. Caligiuri, Robert J. Lee, Ramiro Garzon, Natarajan Muthusamy, Ly James Lee, Guido Marcucci
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (9): 2355–2367.
https://doi.org/10.1158/1078-0432.CCR-12-3191
Published: 30 April 2013
View articletitled, Targeted Delivery of microRNA-29b by Transferrin-Conjugated Anionic Lipopolyplex Nanoparticles: A Novel Therapeutic Strategy in Acute Myeloid Leukemia
Open the PDF for Targeted Delivery of microRNA-29b by Transferrin-Conjugated Anionic Lipopolyplex Nanoparticles: A Novel Therapeutic Strategy in Acute Myeloid Leukemia in another window
Includes: Supplementary data
Journal Articles

Milatuzumab-Conjugated Liposomes as Targeted Dexamethasone Carriers for Therapeutic Delivery in CD74+ B-cell Malignancies

Free
Yicheng Mao, Georgia Triantafillou, Erin Hertlein, William Towns, Matthew Stefanovski, Xiaokui Mo, David Jarjoura, Mitch Phelps, Guido Marcucci, Ly James Lee, David M. Goldenberg, Robert J. Lee, John C. Byrd, Natarajan Muthusamy
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (2): 347–356.
https://doi.org/10.1158/1078-0432.CCR-12-2046
Published: 16 January 2013
View articletitled, Milatuzumab-Conjugated Liposomes as Targeted Dexamethasone Carriers for Therapeutic Delivery in CD74+ B-cell Malignancies
Open the PDF for Milatuzumab-Conjugated Liposomes as Targeted Dexamethasone Carriers for Therapeutic Delivery in CD74+ B-cell Malignancies in another window
Includes: Supplementary data
Journal Articles

Phase I Study of GTI-2040, an Antisense to Ribonucleotide Reductase, in Combination with High-Dose Cytarabine in Patients with Acute Myeloid Leukemia

Free
Rebecca B. Klisovic, William Blum, Xiaohui Wei, Shujun Liu, Zhongfa Liu, Zhiliang Xie, Tamara Vukosavljevic, Cheryl Kefauver, LeNguyen Huynh, Jiuxia Pang, James A. Zwiebel, Steven Devine, John C. Byrd, Michael R. Grever, Kenneth Chan, Guido Marcucci
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (12): 3889–3895.
https://doi.org/10.1158/1078-0432.CCR-08-0109
Published: 16 June 2008
View articletitled, Phase I Study of GTI-2040, an Antisense to Ribonucleotide Reductase, in Combination with High-Dose Cytarabine in Patients with Acute Myeloid Leukemia
Open the PDF for Phase I Study of GTI-2040, an Antisense to Ribonucleotide Reductase, in Combination with High-Dose Cytarabine in Patients with Acute Myeloid Leukemia in another window
Journal Articles

A Phase I Biological Study of MG98, an Oligodeoxynucleotide Antisense to DNA Methyltransferase 1, in Patients with High-Risk Myelodysplasia and Acute Myeloid Leukemia

Free
Rebecca B. Klisovic, Wendy Stock, Spero Cataland, Marko I. Klisovic, Shujun Liu, William Blum, Margaret Green, Olatoyosi Odenike, Lucy Godley, Jennifer Vanden Burgt, Emily Van Laar, Michael Cullen, A. Robert Macleod, Jeffrey M. Besterman, Gregory K. Reid, John C. Byrd, Guido Marcucci
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (8): 2444–2449.
https://doi.org/10.1158/1078-0432.CCR-07-1320
Published: 15 April 2008
View articletitled, A Phase I Biological Study of MG98, an Oligodeoxynucleotide Antisense to DNA Methyltransferase 1, in Patients with High-Risk Myelodysplasia and Acute Myeloid Leukemia
Open the PDF for A Phase I Biological Study of MG98, an Oligodeoxynucleotide Antisense to DNA Methyltransferase 1, in Patients with High-Risk Myelodysplasia and Acute Myeloid Leukemia in another window
Journal Articles

A Novel Raji-Burkitt's Lymphoma Model for Preclinical and Mechanistic Evaluation of CD52-Targeted Immunotherapeutic Agents

Free
Rosa Lapalombella, Xiaobin Zhao, Georgia Triantafillou, Bo Yu, Yan Jin, Gerard Lozanski, Carolyn Cheney, Nyla Heerema, David Jarjoura, Amy Lehman, L. James Lee, Guido Marcucci, Robert J. Lee, Michael A. Caligiuri, Natarajan Muthusamy, John C. Byrd
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (2): 569–578.
https://doi.org/10.1158/1078-0432.CCR-07-1006
Published: 25 January 2008
View articletitled, A Novel Raji-Burkitt's Lymphoma Model for Preclinical and Mechanistic Evaluation of CD52-Targeted Immunotherapeutic Agents
Open the PDF for A Novel Raji-Burkitt's Lymphoma Model for Preclinical and Mechanistic Evaluation of CD52-Targeted Immunotherapeutic Agents in another window
Journal Articles

HDAC Inhibitors and Cardiac Safety

Free
Manisha H. Shah, Miguel A. Villalona-Calero, Guido Marcucci, John C. Byrd, Michael R. Grever
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (3): 1068.
https://doi.org/10.1158/1078-0432.CCR-06-2380
Published: 08 February 2007
View articletitled, HDAC Inhibitors and Cardiac Safety
Open the PDF for HDAC Inhibitors and Cardiac Safety in another window
Journal Articles

The Combination of the Proteasome Inhibitor Bortezomib and the Bcl-2 Antisense Molecule Oblimersen Sensitizes Human B-Cell Lymphomas to Cyclophosphamide

Free
Owen A. O'Connor, Emily A. Smith, Lorraine E. Toner, Julie Teruya-Feldstein, Stanley Frankel, Mark Rolfe, Xiaohui Wei, Shujun Liu, Guido Marcucci, Kenneth K. Chan, Asher Chanan-Khan
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (9): 2902–2911.
https://doi.org/10.1158/1078-0432.CCR-05-0308
Published: 04 May 2006
View articletitled, The Combination of the Proteasome Inhibitor Bortezomib and the Bcl-2 Antisense Molecule Oblimersen Sensitizes Human B-Cell Lymphomas to Cyclophosphamide
Open the PDF for The Combination of the Proteasome Inhibitor Bortezomib and the Bcl-2 Antisense Molecule Oblimersen Sensitizes Human B-Cell Lymphomas to Cyclophosphamide in another window
Journal Articles

Cellular Uptake and Intracellular Levels of the Bcl-2 Antisense G3139 in Cultured Cells and Treated Patients with Acute Myeloid Leukemia

Free
Guowei Dai, Kenneth K. Chan, Shujun Liu, Dale Hoyt, Susan Whitman, Marko Klisovic, TianSheng Shen, Michael A. Caligiuri, John Byrd, Michael Grever, Guido Marcucci
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (8): 2998–3008.
https://doi.org/10.1158/1078-0432.CCR-04-1505
Published: 18 April 2005
View articletitled, Cellular Uptake and Intracellular Levels of the Bcl-2 Antisense G3139 in Cultured Cells and Treated Patients with Acute Myeloid Leukemia
Open the PDF for Cellular Uptake and Intracellular Levels of the Bcl-2 Antisense G3139 in Cultured Cells and Treated Patients with Acute Myeloid Leukemia in another window
Journal Articles

Understanding the Molecular Basis of Imatinib Mesylate Therapy in Chronic Myelogenous Leukemia and the Related Mechanisms of Resistance: Commentary re: A. N. Mohamed et al., The Effect of Imatinib Mesylate on Patients with Philadelphia Chromosome-positive Chronic Myeloid Leukemia with Secondary Chromosomal Aberrations. Clin. Cancer Res., 9: 1333–1337, 2003.

Free
Guido Marcucci, Danilo Perrotti, Michael A. Caligiuri
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (4): 1248–1252.
Published: 01 April 2003
View articletitled, Understanding the Molecular Basis of Imatinib Mesylate Therapy in Chronic Myelogenous Leukemia and the Related Mechanisms of Resistance: Commentary re: A. N. Mohamed et al., The Effect of Imatinib Mesylate on Patients with Philadelphia Chromosome-positive Chronic Myeloid Leukemia with Secondary Chromosomal Aberrations. Clin. Cancer Res., 9: 1333–1337, 2003.
Open the PDF for Understanding the Molecular Basis of Imatinib Mesylate Therapy in Chronic Myelogenous Leukemia and the Related Mechanisms of Resistance: Commentary re: A. N. Mohamed et al., The Effect of Imatinib Mesylate on Patients with Philadelphia Chromosome-positive Chronic Myeloid Leukemia with Secondary Chromosomal Aberrations. Clin. Cancer Res., 9: 1333–1337, 2003. in another window